Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine and Bevacizumab in Endometrial Cancer
NCT03836157Phase 2Withdrawn
- Sponsor
- University of Oklahoma
- Start
- May 2019
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirvetuximab soravtansine in endometrial cancer (EC), sponsored by University of Oklahoma. Primary endpoints: Response rate of patients who remain progression free at 6 months and Percentage of patients who remain progression free at 6 months. Planned start May 2019; status: withdrawn.
02
Drugs
mirvetuximab soravtansine
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03836157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836157.